according to GB/T 16483 and GB/T 17519



Olmesartan Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
2.2	2024/04/06	717977-00016	Date of first issue: 2016/06/01

1. PRODUCT AND COMPANY IDENTIFICATION

Product name	:	Olmesartan Formulation
Manufacturer or supplier's de	etai	ils
Company	:	Organon & Co.
Address	:	30 Hudson Street, 33nd floor Jersey City, New Jersey, U.S.A 07302
Telephone	:	+1-551-430-6000
Emergency telephone number	:	+1-215-631-6999
E-mail address	:	EHSSTEWARD@organon.com
Recommended use of the ch	em	ical and restrictions on use
Recommended use Restrictions on use	:	Pharmaceutical Not applicable

2. HAZARDS IDENTIFICATION

Emergency Overview

Appearance Colour Odour May damage the unborn child.	:	powder No data available No data available
GHS Classification Reproductive toxicity	:	Category 1A
GHS label elements Hazard pictograms	:	
Signal word	:	Danger
Hazard statements	:	H360D May damage the unborn child.
Precautionary statements	:	Prevention: P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read

according to GB/T 16483 and GB/T 17519



Olmesartan Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
2.2	2024/04/06	717977-00016	Date of first issue: 2016/06/01

and understood. P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Physical and chemical hazards

Not classified based on available information.

Health hazards

May damage the unborn child.

Environmental hazards

Not classified based on available information.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation. Contact with dust can cause mechanical irritation or drying of the skin. May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Olmesartan	144689-63-4	>= 1 -< 10
Cellulose	9004-34-6	>= 1 -< 10

4. FIRST AID MEASURES

General advice	 In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	: If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	 In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse.

according to GB/T 16483 and GB/T 17519



Version 2.2	Revision Date: 2024/04/06		0S Number: 7977-00016	Date of last issue: 2023/09/30 Date of first issue: 2016/06/01
In ca	ase of eye contact	:	If in eyes, rinse w	
lf sw	vallowed	:	Get medical attention if irritation develops and persists.If swallowed, DO NOT induce vomiting.Get medical attention.	
	t important symptoms effects, both acute and yed	:	the skin.	unborn child. can cause mechanical irritation or drying of
Prot	ection of first-aiders	:	 Dust contact with the eyes can lead to mechanical irritation First Aid responders should pay attention to self-protection and use the recommended personal protective equipment when the potential for exposure exists (see section 8). 	
	es to physician	:	Treat symptomati	cally and supportively.
Suit	able extinguishing media	:	Water spray Alcohol-resistant Carbon dioxide (C Dry chemical	
Uns med	uitable extinguishing lia	:	None known.	
Spe fight	cific hazards during fire- ing	:	concentrations, and potential dust exp	dust; fine dust dispersed in air in sufficient nd in the presence of an ignition source is a losion hazard. oustion products may be a hazard to health.
Haz ucts	ardous combustion prod-	:	Carbon oxides	
Spe ods	cific extinguishing meth-	:	cumstances and t Use water spray t	measures that are appropriate to local cir- he surrounding environment. o cool unopened containers. ged containers from fire area if it is safe to do
	cial protective equipment irefighters	:	In the event of fire	e, wear self-contained breathing apparatus. rective equipment.
6. ACCIE	DENTAL RELEASE MEAS	SUF	RES	
tive	sonal precautions, protec- equipment and emer- cy procedures	:	Follow safe handl	ective equipment. ing advice (see section 7) and personal pro- recommendations (see section 8).

Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
---------------------------	---	--

Avoidance of contact

Materials to avoid

Packaging material

Conditions for safe storage

Storage

according to GB/T 16483 and GB/T 17519



Olmesartan Formulation

Version 2.2	Revision Date: 2024/04/06		9S Number: 7977-00016	Date of last issue: 2023/09/30 Date of first issue: 2016/06/01
Methods and materials for containment and cleaning up		:	tainer for disposa Avoid dispersal o with compressed Dust deposits sho es, as these may leased into the at	f dust in the air (i.e., clearing dust surfaces
			employed in the c mine which regula Sections 13 and 2	erial, as well as those materials and items cleanup of releases. You will need to deter- ations are applicable. 15 of this SDS provide information regarding ational requirements.
7. HANDLI	NG AND STORAGE			
Hand	ling			
Techn	ical measures	:	causing an explose Provide adequate	nay accumulate and ignite suspended dust sion. e precautions, such as electrical grounding nert atmospheres.
Local/	Total ventilation	:		ation is unavailable, use with local exhaust
Advice	e on safe handling	:	Do not get on ski Do not breathe du	-

Do not swallow.

sessment

environment.

:

:

:

:

Oxidizing agents

Store locked up. Keep tightly closed.

Avoid contact with eyes.

Keep container tightly closed.

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Keep in properly labelled containers.

Unsuitable material: None known.

Do not store with the following product types:

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the

Store in accordance with the particular national regulations.

Strong oxidizing agents

according to GB/T 16483 and GB/T 17519



Olmesartan Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
2.2	2024/04/06	717977-00016	Date of first issue: 2016/06/01

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type	Control parame-	Basis
		(Form of	ters / Permissible	
		exposure)	concentration	
Olmesartan	144689-63-4	TWA	30 µg/m3 (OEB 3)	Internal
		Wipe limit	300 µg/100 cm ²	Internal
Cellulose	9004-34-6	PC-TWA	10 mg/m3	CN OEL
		TWA	10 mg/m3	ACGIH

Engineering measures	:	All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face con- tainment devices). Minimize open handling.
Personal protective equipment	nt	
Respiratory protection Filter type	:	If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection. Particulates type
Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis- posable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Hand protection		-
Material	:	Chemical-resistant gloves
Remarks Hygiene measures	:	Consider double gloving. If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the work- ing place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures,

according to GB/T 16483 and GB/T 17519



Olmesartan Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
2.2	2024/04/06	717977-00016	Date of first issue: 2016/06/01

industrial hygiene monitoring, medical surveillance and the use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES Appearance 2 powder Colour No data available Odour ÷ No data available **Odour Threshold** No data available ÷ No data available pН 1 Melting point/freezing point 2 No data available Initial boiling point and boiling No data available : range Flash point Not applicable ÷ Evaporation rate 2 No data available Flammability (solid, gas) May form explosive dust-air mixture during processing, han-÷ dling or other means. Flammability (liquids) No data available Upper explosion limit / Upper No data available 1 flammability limit Lower explosion limit / Lower No data available 1 flammability limit Vapour pressure No data available : Relative vapour density No data available 5 Relative density ÷ No data available Density No data available : Solubility(ies) Water solubility No data available ÷ Partition coefficient: n-No data available ÷ octanol/water Auto-ignition temperature ÷ No data available No data available Decomposition temperature 2

Version

2.2

according to GB/T 16483 and GB/T 17519

Revision Date:

SDS Number:

717977-00016



Date of last issue: 2023/09/30

Date of first issue: 2016/06/01

Olmesartan Formulation

2024/04/06

2.2	2024/04/06	11	1911-00016 Date of first issue. 2016/06/01
	Viscosity Viscosity, kinematic	:	No data available
	Explosive properties	:	Not explosive
	Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
	Molecular weight	:	No data available
	Particle characteristics Particle size	:	No data available
0.	STABILITY AND REACTIVITY	(
	Reactivity Chemical stability Possibility of hazardous reac- tions	:	Not classified as a reactivity hazard. Stable under normal conditions. May form explosive dust-air mixture during processing, han- dling or other means. Can react with strong oxidizing agents.
	Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
	Incompatible materials Hazardous decomposition products	:	Oxidizing agents No hazardous decomposition products are known.
1.	TOXICOLOGICAL INFORMAT		N
	Exposure routes	:	Inhalation Skin contact Ingestion Eye contact
	Acute toxicity Not classified based on availa	hla	information
	Product:		
	Acute oral toxicity	:	Acute toxicity estimate: > 5,000 mg/kg Method: Calculation method
	Components:		
	Olmesartan:		
	Acute oral toxicity	:	LD50 (Rat): > 2,000 mg/kg
			LD50 (Mouse): > 2,000 mg/kg
			LD50 (Dog): > 1,500 mg/kg
			7 / 15

according to GB/T 16483 and GB/T 17519



sion	Revision Date: 2024/04/06		DS Number: 7977-00016	Date of last issue: 2023/09/30 Date of first issue: 2016/06/01			
Acute	inhalation toxicity	:	Remarks: No d	ata available			
Acute dermal toxicity		:	: Remarks: No data available				
Cellu	lose:						
Acute	e oral toxicity	:	LD50 (Rat): > 5	5,000 mg/kg			
Acute	e inhalation toxicity	:	LC50 (Rat): > 5 Exposure time: Test atmosphe	4 h			
Acute	e dermal toxicity	:	LD50 (Rabbit):	> 2,000 mg/kg			
-	corrosion/irritation lassified based on ava	ailable	information.				
	ponents:						
<u>Com</u>	pomento.						
Olme	esartan:						
	esartan:	:	No data availal	ble			
Olme Rema Serio Not c	esartan: arks ous eye damage/eye i lassified based on ava	irritati	ion	ble			
Olme Rema Serio Not cl <u>Com</u>	esartan: arks ous eye damage/eye i lassified based on ava ponents:	irritati	ion	ble			
Olme Rema Serio Not cl <u>Com</u> Olme	esartan: arks ous eye damage/eye i lassified based on ava ponents: esartan:	irritati	on information.	ble			
Olme Rema Serio Not cl <u>Com</u>	esartan: arks bus eye damage/eye i lassified based on ava ponents: esartan: ies	irritati	on information. Rabbit Moderate eye i				
Olme Rema Serio Not c Com Olme Speci	esartan: arks bus eye damage/eye i lassified based on ava ponents: esartan: ies lt	irritati	on information. Rabbit				
Olme Rema Serio Not c Com Olme Speci Resu Metho	esartan: arks bus eye damage/eye i lassified based on ava ponents: esartan: ies lt	irritati ailable :	on information. Rabbit Moderate eye i Draize Test				
Olme Rema Serio Not c Com Speci Resu Metho Resp Skin	esartan: arks bus eye damage/eye i lassified based on ava ponents: esartan: ies lt od iratory or skin sensi sensitisation	irritati ailable	information. Rabbit Moderate eye i Draize Test				
Olme Rema Serio Not c Com Olme Speci Resu Metho Resp Skin Not c	esartan: arks bus eye damage/eye i lassified based on ava ponents: esartan: ies lt od iratory or skin sensi sensitisation lassified based on ava	irritati ailable tisatic	information. Rabbit Moderate eye i Draize Test				
Olme Rema Serio Not c Com Speci Resu Metho Resp Skin Not c Resp	esartan: arks bus eye damage/eye i lassified based on ava ponents: esartan: ies lt od iratory or skin sensi sensitisation	irritati ailable tisatic ailable	information. Rabbit Moderate eye i Draize Test on information.				
Olme Rema Serio Not c Com Olme Speci Resu Metho Resp Skin Not c Resp	esartan: arks bus eye damage/eye i lassified based on ava ponents: esartan: ies lt od iratory or skin sensi sensitisation lassified based on ava iratory sensitisation	irritati ailable tisatic ailable	information. Rabbit Moderate eye i Draize Test on information.				
Olme Rema Serio Not c Com Speci Resu Metho Resp Skin Not c Resp Not c Com	esartan: arks ous eye damage/eye i lassified based on ava ponents: esartan: ies lt od iratory or skin sensi sensitisation lassified based on ava iratory sensitisation lassified based on ava	irritati ailable tisatic ailable	information. Rabbit Moderate eye i Draize Test on information.				
Olme Rema Serio Not c Com Olme Speci Resu Metho Resp Skin Not c Resp Not c Com Olme	esartan: arks bus eye damage/eye i lassified based on ava ponents: esartan: ies lt od iratory or skin sensi sensitisation lassified based on ava iratory sensitisation lassified based on ava ponents: esartan: sure routes	irritati ailable tisatic ailable	information. Rabbit Moderate eye i Draize Test on information.				

according to GB/T 16483 and GB/T 17519



Version 2.2	Revision Date: 2024/04/06	SDS Numb 717977-000	
<u>Com</u>	ponents:		
Olme	esartan:		
Geno	otoxicity in vitro		pe: Bacterial reverse mutation assay (AMES) negative
			pe: Mutagenicity (in vitro mammalian cytogenetic test) negative
		Test sy	pe: Chromosome aberration test in vitro stem: Chinese hamster lung cells positive
			pe: Mouse Lymphoma negative
Genc	otoxicity in vivo	Species Cell typ Applica	pe: Micronucleus test s: Mouse e: Bone marrow tion Route: Oral negative
	n cell mutagenicity - ssment	: Weight cell mut	of evidence does not support classification as a germ tagen.
Cellu	llose:		
	otoxicity in vitro		pe: Bacterial reverse mutation assay (AMES) negative
			pe: In vitro mammalian cell gene mutation test negative
Genc	otoxicity in vivo	cytoger Species Applica	pe: Mammalian erythrocyte micronucleus test (in vivo netic assay) s: Mouse tion Route: Ingestion negative
	inogenicity lassified based on ava	ilable informati	ion.
	ponents:		
	esartan:		
Spec Appli	ies cation Route sure time	: Rat : Oral : 2 Years : negative	
Spec	ies	: Mouse	

according to GB/T 16483 and GB/T 17519



Ver 2.2	sion	Revision Date: 2024/04/06		9S Number: 7977-00016	Date of last issue: 2023/09/30 Date of first issue: 2016/06/01
		tion Route Ire time	: : :	Oral 6 Months negative	
	Cellulo Species Applica		:	Rat Ingestion	
	Exposu Result	ire time	:	72 weeks negative	
	-	ductive toxicity mage the unborn child.			
	Compo	onents:			
	Olmes				
	Effects	on fertility	:	Test Type: Fertility Species: Rat Application Route Fertility: NOAEL: Result: No effects	: Oral 1,000 mg/kg body weight
	Effects ment	on foetal develop-	:	Test Type: Develo Species: Rat Application Route Dose: 1000 millign Result: No teratog	: Oral am per kilogram
				Test Type: Develo Species: Rabbit Application Route Dose: 1 milligram Result: No teratog	oral per kilogram
				Symptoms: Malfor weight	
	Reprod sessme	luctive toxicity - As- ent	:	Positive evidence human epidemiolo	of adverse effects on development from ogical studies.
	Cellulo Effects	on fertility	:	Test Type: One-g Species: Rat Application Route Result: negative	eneration reproduction toxicity study
				10/15	

according to GB/T 16483 and GB/T 17519



Olmesartan Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
2.2	2024/04/06	717977-00016	Date of first issue: 2016/06/01

Effects on foetal develop- ment	:	Test Type: Fertility/early embryonic development Species: Rat	
		Application Route: Ingestion	
		Result: negative	

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Not classified based on available information.

Repeated dose toxicity

Components:

Olmesartan:

Species	:	Rat
NOAEL	:	2,000 mg/kg
Application Route	:	Oral
Exposure time	:	24 Months
Remarks	:	No significant adverse effects were reported

Cellulose:

Species	:	Rat
NOAEL	:	>= 9,000 mg/kg
Application Route	:	Ingestion
Exposure time	:	90 Days

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Olmesartan:

Eye contact Ingestion	Symptoms: Eye irritation Symptoms: hypotension Remarks: May cause harm to the unborn child. Based on Human Evidence

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Cellulose:

Toxicity to fish

: LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l

according to GB/T 16483 and GB/T 17519



Olmesartan Formulation

Version 2.2	Revision Date: 2024/04/06	SDS Number: 717977-00016	Date of last issue: 2023/09/30 Date of first issue: 2016/06/01
		Exposure time Remarks: Bas	e: 48 h sed on data from similar materials
Persi	istence and degradabi	lity	
Com	ponents:		
	lose: egradability	: Result: Readi	ly biodegradable.
	ccumulative potential ata available		
	lity in soil ata available		
	r adverse effects		
	ata available		
13. DISPO	OSAL CONSIDERATIO	NS	
Wast	osal methods e from residues aminated packaging	Dispose of in	e of waste into sewer. accordance with local regulations. hers should be taken to an approved waste han-
Cont		dling site for r	ecycling or disposal. se specified: Dispose of as unused product.
14. TRAN	SPORT INFORMATION	1	
Inter	national Regulations		
Prope Class Subs Pack Labe	umber er shipping name s idiary risk ing group	 Not applicable no 	9 9 9 9

IATA-DGR

UN/ID No.	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Packing instruction (cargo aircraft)	:	Not applicable

according to GB/T 16483 and GB/T 17519



Olmesartan Formulation

Version	Revision Date: 2024/04/06	SDS Number:	Date of last issue: 2023/09/30
2.2		717977-00016	Date of first issue: 2016/06/01

Packing instruction (passen- ger aircraft)	:	Not applicable
IMDG-Code		
UN number	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
EmS Code	:	Not applicable

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

: no

Not applicable for product as supplied.

National Regulations

GB 6944/12268

Marine pollutant

:	Not applicable
:	Not applicable
:	no

Special precautions for user

Not applicable

15. REGULATORY INFORMATION

National regulatory information Law on the Prevention and Control of Occupational Diseases

Regulation on the Administration of Precursor Chemicals

Catalogue and Classification of Precursor Chemicals : Not listed

Yangtze River Protection Law

This product does not contain any dangerous chemicals prohibited for inland river transport.

The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

16. OTHER INFORMATION

Revision Date

: 2024/04/06

according to GB/T 16483 and GB/T 17519



Olmesartan Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
2.2	2024/04/06	717977-00016	Date of first issue: 2016/06/01


Further information

Sources of key data used to compile the Safety Data Sheet	:	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen- cy, http://echa.europa.eu/	
Date format	:	yyyy/mm/dd	
Full text of other abbreviations			
ACGIH CN OEL	:	USA. ACGIH Threshold Limit Values (TLV) Occupational exposure limits for hazardous agents in the workplace - Chemical hazardous agents.	
ACGIH / TWA CN OEL / PC-TWA	:	8-hour, time-weighted average Permissible concentration - time weighted average	

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation: DSL - Domestic Substances List (Canada): ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan): ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals: SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Disclaimer

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only





Olmesartan Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
2.2	2024/04/06	717977-00016	Date of first issue: 2016/06/01

to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CN / EN